Intravenous Iron Replacement Products
Customize your policy alerts
Sign up for univerahealthcare Policy PHARMACY-116 alerts
Get alerted when Policy PHARMACY-116 changes without checking for updates manually.
Monitor payer policy activity
This pharmacy management drug policy governs prior authorization and coverage criteria for intravenous iron replacement products (e.g., Injectafer, generic ferric carboxymaltose, Feraheme, Venofer, Ferrlecit, Infed, Monoferric) across multiple lines of business for Univera Healthcare members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Intravenous Iron Replacement
Injectafer and generic ferric carboxymaltose Authorization Criteria
Prior authorization for Injectafer and generic ferric carboxymaltose — must meet ONE of the following (a or b):
NDD‑CKD Authorization Criteria
Additional criteria for adults with non‑dialysis dependent chronic kidney disease (NDD‑CKD):
chunk 19
Initial therapy / coverage criteria
Covered when criteria below are met for adults and pediatric patients > 12 years or for NDD-CKD as specified
chunk 19
chunk 19
Product-specific criteria
Product-specific restrictions and requirements
chunks 19 and 17
chunk 19
chunk 19
Injectafer (ferric carboxymaltose) and generic ferric carboxymaltose are covered only when the prior authorization criteria in this policy are met. Injectafer and ferric carboxymaltose will not be authorized for any non‑FDA approved indication. Requests must meet one of the specified diagnostic and laboratory pathways (e.g., adult heart failure with LVEF <45% and hemoglobin/ferritin/TSAT thresholds, or iron deficiency anemia with documented intolerance or unsatisfactory response to oral iron and age‑specific ferritin/hemoglobin thresholds).
This drug policy governs coverage and prior authorization for intravenous iron products across applicable lines of business, but it does not apply to Medicare Part D and D‑SNP pharmacy benefits. Medications in this policy may apply to other lines of business, including Medicare Advantage, per the policy guidance.
All requests for Injectafer and generic ferric carboxymaltose must comply with product‑specific rules in this policy, including documentation requirements and step/exception criteria. Injectafer and ferric carboxymaltose will not be authorized for non‑FDA approved indications and require a medical reason why Feraheme (ferumoxytol) cannot be used except where specified (patients <18 years or adults with NYHA II/III heart failure with LVEF <45%).
Procedure codes associated with the IV iron products in this policy may be designated per the plan's code key. Codes may be designated as Not medically necessary/appropriate (NMN) or Experimental/Investigational (E/I) per code key; specific code‑level NMN or E/I designations will be applied according to the plan's coding guidance and are not listed here.
Coding, Lab Thresholds, and Clinical Values
Provider Requirements and Documentation
Prior authorization applicability
Prior authorization applies to both new starts and existing users for the Commercial, Essential, Exchange, Child Health Plus, and Medicaid/HARP lines of business. For Medicare Advantage and D‑SNP, prior authorization applies to new starts only.
Feraheme trial or contraindication required
All requests for Injectafer or ferric carboxymaltose must include a medical reason why Feraheme (ferumoxytol) cannot be used, except for patients under 18 years of age or adult patients with NYHA class II or III heart failure with LVEF <45%.
Prior authorization required for specified IV iron products
Prior authorization is required for the listed IV iron products and must include the documentation specified in the policy; all requests will be reviewed for appropriate indication and may be subject to off‑label review per the Off‑Label Use policy.
Step requirement versus Feraheme
Requests for Injectafer or ferric carboxymaltose must demonstrate that Feraheme cannot be used unless the patient is <18 years old or is an adult with NYHA II/III heart failure with LVEF <45%, consistent with the product‑specific requirement.
Step therapy and recertification expectations
Recertification reviews are approved for 1 year at a time and may require that more cost‑effective alternatives be tried as they become available; recertification requires documentation that the patient has had a positive response to treatment.
- Recertification may require trying generics, biosimilars, or other guideline‑supported alternatives when available.
Recertification requires documented positive response
Recertifications will be approved for one year and require documentation demonstrating a positive response to treatment (ongoing benefit) to support continued medical necessity.
- Documentation must show improvement or stability in the disease state or condition.
Clinical documentation required for each request
Clinical documentation must be submitted for each initial request and for recertification requests unless otherwise specified; supporting documentation includes progress notes, prior treatment history, laboratory results, imaging, and other objective or subjective measures.
- For recertification, documentation must demonstrate ongoing benefit and that continued use remains medically necessary.
- Requested dosing must be consistent with FDA‑approved or recognized compendia/off‑label guidelines.
Non‑FDA indications excluded
Injectafer and generic ferric carboxymaltose will not be authorized for any indication that is not FDA‑approved.
Coverage may be contract/benefit dependent
Coverage and utilization management requirements in this policy may vary by contract and benefit language; not all contracts/benefits allow coverage of clinician‑administered drugs through the pharmacy benefit.
- Refer to specific contract/benefit language and renewal dates for exclusions or limits.
Medicaid Drug Rebate Program participation required for Medicaid/HARP coverage
Products manufactured by companies not participating in the Medicaid Drug Rebate Program will not be covered under Medicaid Managed Care/HARP; such products will not be available for Medicaid Managed Care/HARP members.
- Providers should verify manufacturer MDRP participation before submitting requests for Medicaid/HARP members.
Initial Authorization Rules
Initial authorization rules
Prior authorization initial approval
chunk 17
Initial therapy
chunks 19 and 17
Recertification and Continuation Criteria
Recertification for Injectafer/ferric carboxymaltose
Recertification requirements
chunks 19 and 24
Recertification
chunks 24 and 19
Step Therapy Requirements
| Step | Requirement | Notes / Exceptions |
|---|---|---|
| 1 | Prior authorization requires documentation that oral iron was tried and resulted in an unsatisfactory response, was intolerable, or is contraindicated for patients with iron deficiency anemia (IDA) without chronic kidney disease (CKD). | Applies to patients ≥1 year of age; pediatric ferritin/Hb thresholds differ by age (see policy). |
| 1 | For requests for Injectafer (ferric carboxymaltose) or generic ferric carboxymaltose, a medical reason must be provided why Feraheme (ferumoxytol) cannot be used, unless the patient is <18 years of age or an adult with NYHA class II or III heart failure with LVEF <45%. | This Feraheme step requirement is product-specific and must be documented with the prior authorization request. |
| Step | Requirement | Recertification / Additional considerations |
|---|---|---|
| 1 | Step therapy requirements may be imposed in addition to any applicable Local Coverage Determination (LCD) or National Coverage Determination (NCD) requirements. | Prior authorization reviews will ensure consistency with LCD/NCD coverage; providers must supply required documentation for those determinations. |
| 1 | Recertification reviews may require trying more cost-effective alternatives (e.g., generics, biosimilars, or formulary-preferred options) as they become available. | Recertifications require clinical documentation demonstrating ongoing benefit (improvement or stability) and must align with the policy's preferred formulary; requested dosing must be consistent with FDA label or recognized compendia. |
Site of Care Considerations
Site of care may impact approval timeframe
The requested site of care (infusion center, office, hospital outpatient, or home) may affect the approval timeframe and is subject to review by the Health Plan.
- Settings referenced: infusion center, office, hospital outpatient, home
Background and Clinical Rationale
Iron deficiency and iron deficiency anemia (IDA) are common clinical conditions diagnosed by laboratory evidence of reduced hemoglobin and depleted iron stores. Oral iron is first‑line therapy; intravenous iron is appropriate when oral iron is intolerable, ineffective, or in clinical settings such as non‑dialysis dependent chronic kidney disease (NDD‑CKD) or selected heart failure patients. Key laboratory parameters used to define need for IV iron include serum ferritin and transferrin saturation (TSAT), with commonly applied thresholds including ferritin <30 ng/mL for general IDA, ferritin <100 ng/mL or ferritin 100–300 ng/mL with TSAT <20%–30% in inflammatory conditions or CKD, and hemoglobin criteria as specified by patient population (for example, hemoglobin ≤11.5 g/dL for NDD‑CKD adults).
Definitions and Clinical Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.